- Home
- AIM vs RCG Comparison
AIM vs RCG Comparison
Compare AIM & RCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- RCG
- Stock Information
- Founded
- AIM 1966
- RCG 1994
- Country
- AIM United States
- RCG United States
- Employees
- AIM N/A
- RCG N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- RCG Investment Managers
- Sector
- AIM Health Care
- RCG Finance
- Exchange
- AIM Nasdaq
- RCG Nasdaq
- Market Cap
- AIM 15.9M
- RCG 15.6M
- IPO Year
- AIM N/A
- RCG N/A
- Fundamental
- Price
- AIM $0.21
- RCG $2.65
- Analyst Decision
- AIM Strong Buy
- RCG
- Analyst Count
- AIM 2
- RCG 0
- Target Price
- AIM $2.75
- RCG N/A
- AVG Volume (30 Days)
- AIM 672.1K
- RCG 5.9K
- Earning Date
- AIM 11-15-2024
- RCG 01-01-0001
- Dividend Yield
- AIM N/A
- RCG 0.98%
- EPS Growth
- AIM N/A
- RCG N/A
- EPS
- AIM N/A
- RCG N/A
- Revenue
- AIM $190,000.00
- RCG N/A
- Revenue This Year
- AIM N/A
- RCG N/A
- Revenue Next Year
- AIM $1,693.10
- RCG N/A
- P/E Ratio
- AIM N/A
- RCG N/A
- Revenue Growth
- AIM N/A
- RCG N/A
- 52 Week Low
- AIM $0.16
- RCG $1.52
- 52 Week High
- AIM $0.62
- RCG $1.90
- Technical
- Relative Strength Index (RSI)
- AIM 50.86
- RCG 58.16
- Support Level
- AIM $0.19
- RCG $2.32
- Resistance Level
- AIM $0.23
- RCG $2.70
- Average True Range (ATR)
- AIM 0.02
- RCG 0.13
- MACD
- AIM -0.00
- RCG 0.02
- Stochastic Oscillator
- AIM 48.29
- RCG 89.58
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About RCG RENN Fund Inc
RENN Fund Inc is active in the financial services domain. It is a closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, Oil and Gas, medical chemicals, botanical products, and others.